Insider trade

CEO received an award of 2,883 PFE derivative securities

Traded Feb 12, 2026 · Filed Feb 17, 2026

PfizerPFE

2,883
Derivative units · @ $27.47

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 12, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 17, 2026

CEOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001225208-26-001988
Filed / recorded

Feb 17, 2026, 10:18 PM UTC

Added to OQRO

Oct 1, 2026, 11:17 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

PFIZER INC

Issuer CIK

78003

Ticker

PFE

Reporting person

Albert Bourla

Relationship

Director, Officer

Officer title

Chairman & CEO

Security

Phantom Stock Units SSP

Table

Derivative (Table II)

Transaction date

Feb 12, 2026

Transaction code

A

Shares / units

2,883

Price per share

$27.47

Acquired / disposed

Acquired (A)

Shares owned after

757,286

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each unit represents one phantom share of common stock.
These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.